[Efficacy and safety of choline alfoscerate in the preventive therapy of dementia in elderly patients with Mild
E V Ponomareva1, L V Androsova1, S A Krinsky2
1Mental Health Research Center, Moscow, Russia.
Summary
Annual choline alfoscerate (CA) therapy significantly slowed cognitive decline and reduced dementia conversion in patients with mild cognitive impairment (MCI). This suggests CA may be a viable preventive dementia therapy for high-risk individuals.
Area of Science:
- Neurology
- Pharmacology
- Geriatrics
Background:
- Mild cognitive impairment (MCI) is a precursor to dementia, particularly Alzheimer's disease (AD).
- Early intervention strategies are crucial to slow or prevent cognitive decline in at-risk populations.
- Choline alfoscerate (CA) is being investigated for its potential neuroprotective effects.
Purpose of the Study:
- To evaluate the efficacy and safety of annual choline alfoscerate (CA) therapy in preventing the progression of amnesic MCI (aMCI) to dementia.
- To assess CA's potential to slow cognitive deficits over a three-year period.
- To explore predictors of CA's preventive effects in aMCI patients.
Main Methods:
- A three-year, open-label, comparative study involving 100 patients with aMCI.
- Patients were randomized into a therapeutic group (annual CA course therapy) and a comparison group (no therapy).
- Methods included clinical, psychopathological, psychometric, immunological assessments, and follow-up evaluations.
Main Results:
- The CA-treated group showed significantly lower cognitive deficit progression (12.2% vs. 39.1%) and dementia conversion rates (8.2% vs. 26.1%) compared to the control group.
- Significant differences in cognitive functioning were observed across all scales and tests in favor of the CA group throughout the three-year follow-up (p<0.05).
- No adverse events were reported, indicating good safety profile.
Conclusions:
- Annual course therapy with choline alfoscerate (CA) demonstrates efficacy in slowing cognitive decline and reducing dementia conversion in aMCI patients.
- CA represents a potential therapeutic model for preventive dementia therapy in individuals at high risk for AD.
- Further research into predictive markers could optimize CA therapy for personalized dementia prevention.
More Related Videos
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.9K
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.5K
Related Concept Videos
01:22Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
121
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
121
01:26Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
01:30Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
662
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
662
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.1K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.1K